<DOC>
	<DOCNO>NCT00036374</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety infliximab ( Remicade ) patient Juvenile Rheumatoid Arthritis ( JRA ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Infliximab ( Remicade ) Patients With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description>The purpose study determine infliximab combination methotrexate safe effective treatment patient juvenile rheumatoid arthritis . The second purpose study see child 's body react combination study drug methotrexate . Patients receive either infliximab 3 mg/kg 44 week , placebo 14 week follow infliximab 6 mg/kg 30 week . Patients complete original study eligible additional treatment 3 6 mg/kg infliximab every 8 week three year . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive either infliximab 3 mg/kg 44 week , placebo 14 week follow infliximab 6 mg/kg 30 week . Patients complete original study eligible additional treatment 3 6 mg/kg infliximab every 8 week three year</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients must diagnosis juvenile rheumatoid arthritis ( JRA ) polyarticular JRA least 6 month , systemic JRA polyarticular course systemic symptom ( include fever , rash , hepatosplenomegaly , serositis ) 1 year prior study entry , pauciarticular JRA polyarticular course least 6 month prior study entry . The patient least 6 month persistent synovitis screening . The patient must least 5 joint active arthritis ( ie , presence swelling , swell present , limitation motion accompany pain , tenderness , ) time enrollment , least 3 active joint limitation motion accompany pain , tenderness , The patient must least 4 year age , less 18 year ( ie , 4th 18th birthday ) , onset disease age 16 . Patient must pregnant , nursing , plan pregnancy within 6 month last study infusion Patient must incapacitate , largely wholly bedridden , confined wheelchair , little ability ageappropriate self care Patient must rheumatic disease JRA current systemic inflammatory condition ( example , Lyme disease , fibromyalgia , enthesitisrelated arthritis , psoriatic arthritis , systemic lupus erythematosus , infectious reactive arthritis , Reiter 's syndrome , parvovirus infection )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Juvenile rheumatoid arthritis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>remicade</keyword>
</DOC>